The global Inflammatory Bowel Disease market size was valued at USD 13170 million in 2023 and is forecast to a readjusted size of USD 16590 million by 2030 with a CAGR of 3.3% during review period.
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine. Crohn's diseaseand ulcerative colitis are the principal types of inflammatory bowel disease. Crohn's disease affects the small intestine and large intestine, as well as the mouth, esophagus, stomach and the anus, whereas ulcerative colitis primarily affects the colon and the rectum.
Medical treatment of IBD is individualised to each patient. The choice of which drugs to use and by which route to administer them (oral, rectal, injection, infusion) depends on factors including the type, distribution, and severity of the patient's disease, as well as other historical and biochemical prognostic factors, and patient preferences. For example, mesalazine is more useful in ulcerative colitis than in Crohn's disease. Generally, depending on the level of severity, IBD may require immunosuppression to control the symptoms, with drugs such as prednisone, TNF inhibitors, azathioprine (Imuran), methotrexate, or 6-mercaptopurine.
The report includes an overview of the development of the Inflammatory Bowel Disease industry chain, the market status of Hospital (Aminosalicylates, Antibiotics), Clinic (Aminosalicylates, Antibiotics), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Inflammatory Bowel Disease.
Regionally, the report analyzes the Inflammatory Bowel Disease markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Inflammatory Bowel Disease market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Inflammatory Bowel Disease market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Inflammatory Bowel Disease industry.
The report involves analyzing the market at a macro level:
麻豆原创 Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Aminosalicylates, Antibiotics).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Inflammatory Bowel Disease market.
Regional Analysis: The report involves examining the Inflammatory Bowel Disease market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
麻豆原创 Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Inflammatory Bowel Disease market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Inflammatory Bowel Disease:
Company Analysis: Report covers individual Inflammatory Bowel Disease players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Inflammatory Bowel Disease This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Inflammatory Bowel Disease. It assesses the current state, advancements, and potential future developments in Inflammatory Bowel Disease areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Inflammatory Bowel Disease market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
麻豆原创 Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
麻豆原创 Segmentation
Inflammatory Bowel Disease market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
麻豆原创 segment by Type
Aminosalicylates
Antibiotics
Corticosteroids
Biologic therapies (biological drugs)
Others
麻豆原创 segment by Application
Hospital
Clinic
Others
麻豆原创 segment by players, this report covers
Bristol-Myers Squibb Company
Baxter International
Johnson & Johnson
Sanofi-Aventis
Abbott Laboratories
Pluristem Therapeutics
Pfizer
AstraZeneca
Cephalon
Amgen
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Inflammatory Bowel Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Inflammatory Bowel Disease, with revenue, gross margin and global market share of Inflammatory Bowel Disease from 2019 to 2024.
Chapter 3, the Inflammatory Bowel Disease competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Inflammatory Bowel Disease market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Inflammatory Bowel Disease.
Chapter 13, to describe Inflammatory Bowel Disease research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope of Inflammatory Bowel Disease
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Inflammatory Bowel Disease by Type
1.3.1 Overview: Global Inflammatory Bowel Disease 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Inflammatory Bowel Disease Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Aminosalicylates
1.3.4 Antibiotics
1.3.5 Corticosteroids
1.3.6 Biologic therapies (biological drugs)
1.3.7 Others
1.4 Global Inflammatory Bowel Disease 麻豆原创 by Application
1.4.1 Overview: Global Inflammatory Bowel Disease 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Clinic
1.4.4 Others
1.5 Global Inflammatory Bowel Disease 麻豆原创 Size & Forecast
1.6 Global Inflammatory Bowel Disease 麻豆原创 Size and Forecast by Region
1.6.1 Global Inflammatory Bowel Disease 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Inflammatory Bowel Disease 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Inflammatory Bowel Disease 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Inflammatory Bowel Disease 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Inflammatory Bowel Disease 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Inflammatory Bowel Disease 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East and Africa Inflammatory Bowel Disease 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Bristol-Myers Squibb Company
2.1.1 Bristol-Myers Squibb Company Details
2.1.2 Bristol-Myers Squibb Company Major Business
2.1.3 Bristol-Myers Squibb Company Inflammatory Bowel Disease Product and Solutions
2.1.4 Bristol-Myers Squibb Company Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.2 Baxter International
2.2.1 Baxter International Details
2.2.2 Baxter International Major Business
2.2.3 Baxter International Inflammatory Bowel Disease Product and Solutions
2.2.4 Baxter International Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Baxter International Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Inflammatory Bowel Disease Product and Solutions
2.3.4 Johnson & Johnson Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Sanofi-Aventis
2.4.1 Sanofi-Aventis Details
2.4.2 Sanofi-Aventis Major Business
2.4.3 Sanofi-Aventis Inflammatory Bowel Disease Product and Solutions
2.4.4 Sanofi-Aventis Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Sanofi-Aventis Recent Developments and Future Plans
2.5 Abbott Laboratories
2.5.1 Abbott Laboratories Details
2.5.2 Abbott Laboratories Major Business
2.5.3 Abbott Laboratories Inflammatory Bowel Disease Product and Solutions
2.5.4 Abbott Laboratories Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Abbott Laboratories Recent Developments and Future Plans
2.6 Pluristem Therapeutics
2.6.1 Pluristem Therapeutics Details
2.6.2 Pluristem Therapeutics Major Business
2.6.3 Pluristem Therapeutics Inflammatory Bowel Disease Product and Solutions
2.6.4 Pluristem Therapeutics Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 Pluristem Therapeutics Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Inflammatory Bowel Disease Product and Solutions
2.7.4 Pfizer Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Inflammatory Bowel Disease Product and Solutions
2.8.4 AstraZeneca Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 AstraZeneca Recent Developments and Future Plans
2.9 Cephalon
2.9.1 Cephalon Details
2.9.2 Cephalon Major Business
2.9.3 Cephalon Inflammatory Bowel Disease Product and Solutions
2.9.4 Cephalon Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 Cephalon Recent Developments and Future Plans
2.10 Amgen
2.10.1 Amgen Details
2.10.2 Amgen Major Business
2.10.3 Amgen Inflammatory Bowel Disease Product and Solutions
2.10.4 Amgen Inflammatory Bowel Disease Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Amgen Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Inflammatory Bowel Disease Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Inflammatory Bowel Disease by Company Revenue
3.2.2 Top 3 Inflammatory Bowel Disease Players 麻豆原创 Share in 2023
3.2.3 Top 6 Inflammatory Bowel Disease Players 麻豆原创 Share in 2023
3.3 Inflammatory Bowel Disease 麻豆原创: Overall Company Footprint Analysis
3.3.1 Inflammatory Bowel Disease 麻豆原创: Region Footprint
3.3.2 Inflammatory Bowel Disease 麻豆原创: Company Product Type Footprint
3.3.3 Inflammatory Bowel Disease 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Inflammatory Bowel Disease Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Inflammatory Bowel Disease 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Inflammatory Bowel Disease Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Inflammatory Bowel Disease 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Inflammatory Bowel Disease Consumption Value by Type (2019-2030)
6.2 North America Inflammatory Bowel Disease Consumption Value by Application (2019-2030)
6.3 North America Inflammatory Bowel Disease 麻豆原创 Size by Country
6.3.1 North America Inflammatory Bowel Disease Consumption Value by Country (2019-2030)
6.3.2 United States Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Inflammatory Bowel Disease Consumption Value by Type (2019-2030)
7.2 Europe Inflammatory Bowel Disease Consumption Value by Application (2019-2030)
7.3 Europe Inflammatory Bowel Disease 麻豆原创 Size by Country
7.3.1 Europe Inflammatory Bowel Disease Consumption Value by Country (2019-2030)
7.3.2 Germany Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Inflammatory Bowel Disease Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Inflammatory Bowel Disease Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Inflammatory Bowel Disease 麻豆原创 Size by Region
8.3.1 Asia-Pacific Inflammatory Bowel Disease Consumption Value by Region (2019-2030)
8.3.2 China Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Inflammatory Bowel Disease Consumption Value by Type (2019-2030)
9.2 South America Inflammatory Bowel Disease Consumption Value by Application (2019-2030)
9.3 South America Inflammatory Bowel Disease 麻豆原创 Size by Country
9.3.1 South America Inflammatory Bowel Disease Consumption Value by Country (2019-2030)
9.3.2 Brazil Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Inflammatory Bowel Disease Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Inflammatory Bowel Disease Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Inflammatory Bowel Disease 麻豆原创 Size by Country
10.3.1 Middle East & Africa Inflammatory Bowel Disease Consumption Value by Country (2019-2030)
10.3.2 Turkey Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Inflammatory Bowel Disease 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Inflammatory Bowel Disease 麻豆原创 Drivers
11.2 Inflammatory Bowel Disease 麻豆原创 Restraints
11.3 Inflammatory Bowel Disease Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Inflammatory Bowel Disease Industry Chain
12.2 Inflammatory Bowel Disease Upstream Analysis
12.3 Inflammatory Bowel Disease Midstream Analysis
12.4 Inflammatory Bowel Disease Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Bristol-Myers Squibb Company
Baxter International
Johnson & Johnson
Sanofi-Aventis
Abbott Laboratories
Pluristem Therapeutics
Pfizer
AstraZeneca
Cephalon
Amgen
听
听
*If Applicable.
